As shown in Figure 3A, tiliroside (25.0 and 50.0 mg/kg) treatments significantly decreased the percentage of M1 macrophage phenotype (CD68+ iNOS+ double labeled) and upregulated M2 macrophage phenotype (CD68+ CD206+ double labeled) in the colonic lamina propria of colitis mice. This evidence concerns the gene MRC1 and colitis.